

Otsuka Medical Devices to Transfer Spine and Trauma Businesses of KiSCO Through Absorption-Type Split
--

By Concluding Agreement with Teijin Nakashima Medical

Otsuka Medical Devices Co., Ltd., a wholly-owned subsidiary of Otsuka Holdings Co., Ltd., announced today that it has signed an agreement with Teijin Nakashima Medical Co., Ltd. to transfer the spine and trauma (fracture) businesses of its subsidiary, KiSCO Co., Ltd., through an absorption-type split.

Otsuka Medical Devices plans to complete the transfer of human resources and products from KiSCO's spine and trauma businesses and the operations shall start under the new organization on the 1st day of February 2022.

Background and Timeline

- Otsuka Medical Devices acquired KiSCO in October 2011 in order to enter the orthopedics area. KiSCO has been contributing to human health by developing, introducing and marketing innovative products in the spine and trauma fields.
- Otsuka Medical Devices is currently focusing on research and development in the fields of renal and endovascular therapies and apheresis,* aiming to provide new treatment options using cutting-edge medical devices.
- As the Teijin Group's manufacturer of implantable medical devices for orthopedics, Teijin Nakashima Medical has a strong affinity with KiSCO's business. Recognizing that Teijin Nakashima Medical had the foundation to accelerate the growth of KiSCO's business, Otsuka Medical Devices agreed to the transfer it through an absorption-type split.

As of November 30, 2022, KiSCO Co., Ltd. has completed the liquidation. (Updated on December 1, 2022)

Company Profiles

KiSCO Co., Ltd.

Name	KiSCO Co., Ltd.
Head office	5-3-6 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo Prefecture, Japan
Established	September 14, 1968
Capital	1,932,060,000 yen
Representative	Ayumu Nakaji, President and Representative Director
Number of employees	91 (as of April 1, 2021)

Description of business	Development, import, manufacture and sale of medical devices
Website	https://www.kisco.jp/en/

Teijin Nakashima Medical Co., Ltd.

Name	Teijin Nakashima Medical Co., Ltd.
Head office	688-1 Joto-Kitagata, Higashi-ku, Okayama, Okayama Prefecture, Japan
Established	September 3, 2008
Capital	100 million yen
Representative	Katsuhiko Yokota, President
Number of employees	288 (As of October 16, 2021)
Description of business	Development, manufacturing, and distribution of medical devices, such as artificial joints, trauma devices, and spinal devices
Website	https://www.teijin-nakashima.co.jp/en/

Otsuka Medical Devices Co., Ltd.

Name	Otsuka Medical Devices Co., Ltd.
Head office	2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, Japan
Established	February 15, 2011
Capital	7.55 billion yen
Representative	Noriko Tojo, President and Representative Director
Number of employees	89 (As of June 30, 2021)
Description of business	Overseeing medical device operations within the Otsuka Group and the business activities of companies engaged in related businesses, as well as all operations incidental to the foregoing activities.
Website	https://www.umd.otsuka.com/en/

Reference

* Apheresis: A minimally invasive treatment method that separates plasma and cellular constituents in the blood via extracorporeal therapy techniques. The process also separates and removes harmful fluid factors, such as antibodies, inflammatory cytokines, metabolites, and toxic substances.

Media contact:

OMD-PR@otsuka.jp